<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991324</url>
  </required_header>
  <id_info>
    <org_study_id>2021-xxxxxx</org_study_id>
    <nct_id>NCT04991324</nct_id>
  </id_info>
  <brief_title>Cholecalciferol Comedication in IBD - the 5C Study</brief_title>
  <acronym>5C</acronym>
  <official_title>Cholecalciferol Comedication in Chronic Inflammatory Bowel Diseases (Crohn's Disease or Ulcerative Colitis) - the 5C Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency (defined as 25(OH)-vitamin D serum level &lt;50 nmol/ l) is associated with&#xD;
      irritable bowel disease (IBD). National guidelines recommend the administration of 800 -4000&#xD;
      IU cholecalciferol daily for an effective treatment, especially during the winter (poor sun&#xD;
      exposition). Cumulative intermittent administration monthly or weekly is possible. The study&#xD;
      aims to compare inflammation activity (primary outcome) after monthly or weekly treatment&#xD;
      with soft capsules containing 24'000 IU cholecalciferol compared to no vitamin D&#xD;
      supplementation. Quantification of 25(OH)-vitamin D serum values is a secondary outcome. The&#xD;
      investigators will use newly developed soft capsules.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monthly supplementation: Monthly administration of a capsule containing 24'000 IU vitamin D,&#xD;
      corresponding to a dose of approximately 800 IU per day, as comedication to the usual&#xD;
      treatment during 6 months.&#xD;
&#xD;
      Weekly supplementation: Weekly administration of a capsule containing 24'000 IU vitamin D,&#xD;
      corresponding a dose of approximately 3500 IU per day, as comedication to the usual treatment&#xD;
      during 6 months.&#xD;
&#xD;
      Control: Usual treatment without vitamin D supplementation. All 3 groups: In a follow-up&#xD;
      phase of 6 months, all participants can choose whether they want a monthly vitamin D&#xD;
      supplementation or not.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2022</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment Patient will be recruited by their regularly visit. Patients will be randomly assigned to be supplemented with monthly capsules (monthly group), weekly capsules (weekly group) or no supplementation (control group).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fecal calprotectin</measure>
    <time_frame>every 2 months during 6 months</time_frame>
    <description>laboratory disease activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>(OH)-vitamin D serum value</measure>
    <time_frame>every 2 months during 6 months</time_frame>
    <description>serum value cholecalciferol</description>
  </secondary_outcome>
  <other_outcome>
    <measure>disease activity score</measure>
    <time_frame>every 2 months during 6 months</time_frame>
    <description>clinical disease activity</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>weekly supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 3500 IU per day, as comedication to the usual treatment during 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monthly supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monthly administration of a capsule containing 24'000 IU vitamin D, corresponding to a dose of approximately 800 IU per day, as comedication to the usual treatment during 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual treatment without vitamin D supplementation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>24,000 IU cholecalciferol</description>
    <arm_group_label>monthly supplementation</arm_group_label>
    <arm_group_label>weekly supplementation</arm_group_label>
    <other_name>D3 VitaCaps</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of Crohn disease or ulcerative colitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hypercalcaemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Allemann, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Pharmaceutical Care Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre Rothen, PhD</last_name>
    <phone>+41 61 207 15 67</phone>
    <email>jp.rothen@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petr Hr√∫z, Prof.</last_name>
    <phone>+41 61 777 75 75</phone>
    <email>petr.hruz@clarunis.ch</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

